Business
GPX: Revenue doubled and EBITDA turned positive in Q1 2026, driven by pharma and food growth
GPX: Revenue doubled and EBITDA turned positive in Q1 2026, driven by pharma and food growth
About this update from Gasporox Ab
Strong Q1 2026 performance with revenue more than doubling year-over-year and positive EBITDA. Growth driven by pharmaceutical and food sectors, new product launches, and expanded customer base. Investments and strategic hires support continued expansion.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.